The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -2.40 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -2.78 — no flag raisedOK
- Earnings quality 81/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Guardant Health, Inc. reports it. History and quarterly detail are in the app.
- Oncology$683.6M
- Biopharma and data$210.1M
- Screening$79.7M
- Licensing and other$8.6M
Leadership changes
From Guardant Health, Inc.'s own filings, the day they're filed.
- Craig Eagle · Chief Medical Officer · departureeff. 2026-05-08
- Alex M. Azar II · director · appointmenteff. 2025-09-12
- Roberto Mignone · director · appointmenteff. 2024-10-21
Latest filings
- 8-K · Company announcement2026-06-18
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-07
- DEF 14A · Annual proxy (pay & governance)2026-04-28
- 8-K · Company announcement2026-04-27
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Guardant Health, Inc., every answer cited🔒
- The Intelligence Brief — added when Guardant Health, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.